These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27158940)

  • 1. The future of immunotherapy for sarcoma.
    Tsukahara T; Emori M; Murata K; Mizushima E; Shibayama Y; Kubo T; Kanaseki T; Hirohashi Y; Yamashita T; Sato N; Torigoe T
    Expert Opin Biol Ther; 2016 Aug; 16(8):1049-57. PubMed ID: 27158940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
    Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
    J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Sarcoma: Future Horizons.
    Burgess M; Gorantla V; Weiss K; Tawbi H
    Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.
    Frankiw L; Singh A; Peters C; Comin-Anduix B; Berent-Maoz B; Macabali M; Shammaie K; Quiros C; Kaplan-Lefko P; Baselga Carretero I; Ribas A; Nowicki TS
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37156551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
    Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
    J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy against sarcomas.
    Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
    Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of engineered T-cell therapy for synovial sarcoma.
    Dallos M; Tap WD; D'Angelo SP
    Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
    Sebio A; Wilky BA; Keedy VL; Jones RL
    Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
    Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
    J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising immunotherapies for esophageal cancer.
    Tanaka T; Nakamura J; Noshiro H
    Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
    Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
    Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell immunotherapy in soft tissue sarcoma.
    Indelicato DJ; Finkelstein SE
    Immunotherapy; 2012 Oct; 4(10):1023-9. PubMed ID: 23148754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for immunotherapy in soft tissue sarcoma.
    Tseng WW; Somaiah N; Engleman EG
    Hum Vaccin Immunother; 2014; 10(11):3117-24. PubMed ID: 25625925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic strategies: the melanoma example.
    Jorritsma A; Schumacher TN; Haanen JB
    Immunotherapy; 2009 Jul; 1(4):679-90. PubMed ID: 20635992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.